Business Description

Overview Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 currently under review at the FDA for the treatment of dermatomyositis and also in late stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Pipeline The following table summarizes selected product candidates from our pipeline. Product Candidate Indication Vant Modality Phase Brepocitinib Dermatomyositis Priovant Small Molecule PDUFA Date 3Q 2026 Brepocitinib Non-Infectious Uveitis Priovant Small Molecule Phase 3* Brepocitinib Cutaneous Sarcoidosis Priovant Small Molecule Phase 3* Brepocitinib Lichen Planopilaris Priovant Small Molecule Phase 2b/3* IMVT-1402 Difficult-to-Treat Rheumatoid Arthritis Immunovant Biologic Phase 2/3* IMVT-1402 Graves’ Disease Immunovant Biologic Phase 2/3* IMVT-1402 Myasthenia Gravis Immunovant Biologic Phase 2/3* IMVT-1402 Chronic Inflammatory Demyelinating Polyneuropathy Immunovant Biologic Phase 2/3* IMVT-1402 Sjögren’s Disease Immunovant Biologic Phase 2/3* IMVT-1402 Cutaneous Lupus Erythematosus Immunovant Biologic Phase 2 Mosliciguat Pulmonary Hypertension associated with Interstitial Lung Disease Pulmovant Inhaled Phase 2 Note: All product candidates in our current pipeline are investigational and subject to health authority approval. The “Phase” for a specific product candidate referenced above reflects both ongoing clinical trials and expected upcoming trials. * Indicates registrational or potentially registrational trials. The Vant Model The Vant model unlocks key strategic advantages for Roivant and, we believe, ultimately enables us to develop transformative medicines for diseases for which there are no approved therapies or where the current standard of care treatment has significant limitations faster than our competitors. We believe we are uniquely positioned to accomplish this by: • Leveraging our business development expertise to identify and in-license promising drug candidates: We assembled our product candidate pipeline by leveraging our business development expertise and vast network 7 Table of Contents of industry relationships to relentlessly pursue opportunities to in-license or acquire programs where we believe we can deliver successful outcomes on accelerated timelines. Our pipeline expansion has been enabled by our strong track record of rapid and high-quality execution, as well as our ability to maintain a robust balance sheet to fund programs through development. • Creating nimble, entrepreneurial Vants : Vants operate similarly to independent biotechnology companies where each management team is focused on its respective mission and is economically incentivized to maximize value through Vant-specific equity grants. Each of our Vant teams is built with deep relevant expertise to ensure successful execution of its particular development strategy. The Vant model is designed to facilitate rapid decision making and calculated risk taking, by empowering, aligning and incentivizing Vant teams around the outcomes of their specific product candidates. • Allocating capital to maximize R&D efficiency: We apply an objective, rigorous decision-making framework across the drug development process designed to ensure resources and capital are continuously directed towards programs we believe have the highest probability of success and away from those that fail to meet our rigorous internal hurdles.…